What is Abtrace?
Abtrace is a London-based health technology company that employs sophisticated machine learning algorithms to address the complexities of chronic and long-term health conditions. By focusing on early detection, continuous monitoring, and effective treatment strategies, Abtrace aims to revolutionize patient care and improve health outcomes for individuals managing persistent health challenges. The company's innovative approach positions it at the forefront of digital health solutions.
How much funding has Abtrace raised?
Abtrace has raised a total of $2.9M across 1 funding round:
Angel/Seed
$2.9M
Angel/Seed (2021): $2.9M with participation from Faber SpA and Ganexa Capital
Key Investors in Abtrace
Faber SpA
Faber SpA, a global industrial group with fifty years of experience in manufacturing, is a significant backer. While primarily known for its leadership in the appliance sector, its investment in Abtrace suggests a diversification into health technology or a strategic interest in innovative solutions.
Ganexa Capital
Ganexa Capital is a business angel firm that actively invests in entrepreneurial projects, particularly those with a technological focus and the potential to address unmet market needs. Their involvement indicates a belief in Abtrace's innovative approach and its capacity for global impact.
What's next for Abtrace?
With a recent major strategic investment and substantial overall backing, Abtrace is poised for significant expansion and further development of its machine learning-driven health technology platform. This capital infusion is expected to accelerate product innovation, enhance market penetration, and potentially explore new therapeutic areas or technological advancements. The company's trajectory suggests a focus on scaling its operations and solidifying its position as a leader in the health tech sector, particularly in the realm of chronic disease management.
See full Abtrace company page
